Armata’s AP-SA02 Receives FDA Breakthrough Designation
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Los Angeles, California, U.S., September 14, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has...
